Showing 5 posts of 5 posts found.

FDA gives Orphan Drug Designation to Faron Pharmaceuticals’ Bexmarilimab

August 29, 2023
Research and Development FDA, Faron, ODD, Oncology, leukemia

Faron Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its …


Kite’s leukaemia cell therapy application validated by EMA

June 24, 2021
EMA, Kite, leukemia

Kite has announced that their Type II variation application for a new indication to the approved license for autologous anti-CD19-transduced …


MHRA approves venetoclax as acute myeloid leukemia treatment

June 8, 2021
Manufacturing and Production EC, EU, MHRA, leukemia

The MHRA has announced its approval for AbbVie’s venetoclax, in combination with a hypomethylating agent, for the treatment of newly …

Pfizer’s Bosulif scores US green light in leukaemia sub-type

December 21, 2017
Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma

Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …

Ariad expands in Europe

February 22, 2013
Sales and Marketing Ariad, leukaemia, leukemia

The new European boss of Ariad Pharmaceuticals has sketched out the US firm’s plans for its next-generation leukaemia drug, which …

Latest content